Cargando…

Are we fully exploiting type I Interferons in today's fight against COVID-19 pandemic?

Coronavirus disease 2019 (COVID-19) first emerged in late 2019 in China. At the time of writing, its causative agent SARS-CoV-2 has spread worldwide infecting over 9 million individuals and causing more than 460,000 deaths. In the absence of vaccines, we are facing the dramatic challenge of controll...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aricò, Eleonora, Bracci, Laura, Castiello, Luciano, Gessani, Sandra, Belardelli, Filippo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334951/ https://www.ncbi.nlm.nih.gov/pubmed/32665127 http://dx.doi.org/10.1016/j.cytogfr.2020.07.010

Ejemplares similares

Exploiting natural antiviral immunity for the control of pandemics: Lessons from Covid-19
por: Aricò, Eleonora, et al.
Publicado: (2022)

Type I Interferons and Cancer: An Evolving Story Demanding Novel Clinical Applications
por: Aricò, Eleonora, et al.
Publicado: (2019)

Type I Interferons as Joint Regulators of Tumor Growth and Obesity
por: Gessani, Sandra, et al.
Publicado: (2021)

Type I Interferons as Regulators of Human Antigen Presenting Cell Functions
por: Gessani, Sandra, et al.
Publicado: (2014)

In situ Vaccination by Direct Dendritic Cell Inoculation: The Coming of Age of an Old Idea?
por: Castiello, Luciano, et al.
Publicado: (2019)

Immune Dysfunctions and Immunotherapy in Colorectal Cancer: The Role of Dendritic Cells
por: Gessani, Sandra, et al.
Publicado: (2019)

Concomitant detection of IFNα signature and activated monocyte/dendritic cell precursors in the peripheral blood of IFNα-treated subjects at early times after repeated local cytokine treatments
por: Aricò, Eleonora, et al.
Publicado: (2011)

Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial
por: Aricò, Eleonora, et al.
Publicado: (2021)

Exploiting the transatlantic fight path
Publicado: (2004)

Blood immune cells as potential biomarkers predicting relapse-free survival of stage III/IV resected melanoma patients treated with peptide-based vaccination and interferon-alpha
por: Moschella, Federica, et al.
Publicado: (2023)

Interferon Lambda: Opportunities, Risks, and Uncertainties in the Fight Against HCV
por: Laidlaw, Stephen M., et al.
Publicado: (2014)

Anticancer Effects of Sublingual Type I IFN in Combination with Chemotherapy in Implantable and Spontaneous Tumor Models
por: Ciccolella, Maria, et al.
Publicado: (2021)

Benign Bone Tumors: An Overview of What We Know Today
por: De Salvo, Sara, et al.
Publicado: (2022)

Leishmaniasis Vaccine: Where are We Today?
por: Kedzierski, Lukasz
Publicado: (2010)

What did we learn today?
por: Midtvedt, Tore
Publicado: (2015)

Pathology of thymoma—where are we today?
por: Soomro, Irshad Nabi
Publicado: (2020)

Ocular tuberculosis: Where are we today?
por: Testi, Ilaria, et al.
Publicado: (2020)

Refractive surgery: Where are we today?
por: Sachdev, Mahipal S
Publicado: (2020)

Circular Health: exploiting the SDG roadmap to fight AMR
por: Mantegazza, Luca, et al.
Publicado: (2023)

Are we winning the fight?
por: Damle, S. G.
Publicado: (2014)

Type I Interferon as a Powerful Adjuvant for Monocyte-Derived Dendritic Cell Development and Activity in Vitro and in Hu-Pbl-Scid Mice
por: Santini, Stefano M., et al.
Publicado: (2000)

ICSBP Is Essential for the Development of Mouse Type I Interferon-producing Cells and for the Generation and Activation of CD8α(+) Dendritic Cells
por: Schiavoni, Giovanna, et al.
Publicado: (2002)

Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma
por: Rozera, Carmela, et al.
Publicado: (2015)

What did we learn in school today ?
por: Tröster, D A
Publicado: (1989)

HIV-2 Infection: Where Are We Today?
por: Ingole, Nayana A., et al.
Publicado: (2013)

Laboratory Information System – Where are we Today?
por: Lukić, Vera
Publicado: (2017)

Preimplantation Genetic Testing: Where We Are Today
por: Greco, Ermanno, et al.
Publicado: (2020)

Cryopreservation of single-sperm: where are we today?
por: Liu, Shasha, et al.
Publicado: (2020)

Exploiting the mechanism of estrogen-induced transcription to fight breast cancer
por: Perillo, Bruno, et al.
Publicado: (2021)

Chemo-immunotherapy induces tumor regression in a mouse model of spontaneous mammary carcinogenesis
por: Aricò, Eleonora, et al.
Publicado: (2016)

Robotic Radical Cystectomy: Where are We Today, Where will We be Tomorrow?
por: Richards, Kyle A., et al.
Publicado: (2010)

Cataract surgery – Where are we today and what do we need?
por: Heda, Aarti, et al.
Publicado: (2022)

Till we win: Indian's fight against the COVID-19 pandemic
Publicado: (2021)

Delayed polarization of mononuclear phagocyte transcriptional program by type I interferon isoforms
por: Stroncek, David F, et al.
Publicado: (2005)

Retrograde intra-renal surgery: Where are we today?
por: Chibber, Percy Jal
Publicado: (2008)

Multiple sclerosis: As we see it today and glimpses of tomorrow
por: Rammohan, Kottil W.
Publicado: (2009)

Magnetic Resonance Coronary Angiography: Where Are We Today?
por: Chiribiri, Amedeo, et al.
Publicado: (2013)

Pneumococcal vaccination in older persons: where are we today?
por: Van Buynder, Paul, et al.
Publicado: (2018)

Scleral surgery for the treatment of presbyopia: where are we today?
por: Hipsley, AnnMarie, et al.
Publicado: (2018)

Precision diabetes: Where do we stand today?
por: Mohan, Viswanathan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_urrcr8siandfk7ij1vvqrundof